BGLA Stock Overview
A healthcare company, provides probiotic products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
BioGaia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 8.92 |
| 52 Week High | SEK 11.63 |
| 52 Week Low | SEK 8.36 |
| Beta | 0.59 |
| 11 Month Change | 4.33% |
| 3 Month Change | -19.25% |
| 1 Year Change | -5.21% |
| 33 Year Change | -10.40% |
| 5 Year Change | 24.34% |
| Change since IPO | 923.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| BGLA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.7% | -0.7% | -0.02% |
| 1Y | -5.2% | -17.2% | 8.2% |
Return vs Industry: BGLA exceeded the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: BGLA underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| BGLA volatility | |
|---|---|
| BGLA Average Weekly Movement | 4.2% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BGLA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BGLA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 222 | Theresa Agnew | www.biogaia.com |
BioGaia AB (publ), a healthcare company, provides probiotic products worldwide. The company operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula.
BioGaia AB (publ) Fundamentals Summary
| BGLA fundamental statistics | |
|---|---|
| Market cap | €930.71m |
| Earnings (TTM) | €29.29m |
| Revenue (TTM) | €117.89m |
31.8x
P/E Ratio7.9x
P/S RatioIs BGLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BGLA income statement (TTM) | |
|---|---|
| Revenue | SEK 1.36b |
| Cost of Revenue | SEK 358.07m |
| Gross Profit | SEK 997.60m |
| Other Expenses | SEK 660.78m |
| Earnings | SEK 336.82m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 12, 2025
| Earnings per share (EPS) | 3.33 |
| Gross Margin | 73.59% |
| Net Profit Margin | 24.85% |
| Debt/Equity Ratio | 0% |
How did BGLA perform over the long term?
See historical performance and comparison